Oncogenic tuftelin 1 as a potential molecular-targeted for inhibiting hepatocellular carcinoma growth

doi:10.3748/wjg.v27.i23.3327

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 27, Issue 23

This Article

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (9377)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-6) series, Tables (1-3) series.

Item

Count

PDF

504

WORD

224

HTML

3904

Figures (1-6)

548

Tables (1-3)

469

Sum=5649

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

450

Download

1015

Sum=1465

Publishing Process of This Article

Item

Count

Browse

634

Download

1628

Sum=2262

Jun 21, 2021 (publication date) through Mar 2, 2026

Times Cited of This Article

Times Cited (5)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article with Cover (PDF)
- Full Article (XML)

Basic Study

World J Gastroenterol. Jun 21, 2021; 27(23): 3327-3341
Published online Jun 21, 2021. doi: 10.3748/wjg.v27.i23.3327

Oncogenic tuftelin 1 as a potential molecular-targeted for inhibiting hepatocellular carcinoma growth

Meng-Na Wu, Wen-Jie Zheng, Wen-Xin Ye, Li Wang, Ying Chen, Jie Yang, Deng-Fu Yao, Min Yao

Meng-Na Wu, Wen-Jie Zheng, Deng-Fu Yao, Research Center of Clinical Medicine, The Affiliated Hospital of Nantong University, Nantong 226001, Jiangsu Province, China

Wen-Xin Ye, Min Yao, Department of Medical Immunology, Medical School of Nantong University, Nantong 226001, Jiangsu Province, China

Li Wang, Department of Medical Informatics, Medical School of Nantong University, Nantong 226001, Jiangsu Province, China

Ying Chen, Department of Oncology, The Affiliated Second Hospital of Nantong University, Nantong 226001, Jiangsu Province, China

Jie Yang, Department of Molecular Biology, Life Science School of Nantong University, Nantong 226009, Jiangsu Province, China

Author contributions: Wu MN, Zheng WJ, and Ye WX contributed equally to this work and wrote the first draft; Wang L, Chen Y, and Yang J contributed to the methodology, data curation, and formal analysis; Yao M and Yao DF revised the manuscript. All authors approved the final version of the manuscript.

Supported by Projects of the Ministry of Science and Technology, National Key Research and Development Program, No. 2018YFC0116902; National Natural Science Foundation of China, No. 81673241, No. 31872738, No. 81873915.

Institutional review board statement: This study was approved by the Ethics Committee of the Affiliated Hospital of Nantong University (TDFY2018-025), China.

Conflict-of-interest statement: No benefits in any form have been received or will be received from a commercial party related directly or indirectly to the subject of this article.

Data sharing statement: No additional data are available.

Corresponding author: Deng-Fu Yao, MD, PhD, Director, Full Professor, Research Center of Clinical Medicine, The Affiliated Hospital of Nantong University, No. 20 West Temple Road, Nantong 226001, Jiangsu Province, China. yaodf@ahnmc.com

Received: December 14, 2020
Peer-review started: December 14, 2020
First decision: December 27, 2020
Revised: January 6, 2021
Accepted: May 19, 2021
Article in press: May 19, 2021
Published online: June 21, 2021
Processing time: 185 Days and 22.1 Hours

Core Tip

Core Tip: Tuftelin1 (TUFT1) has been reported to be regulated by hypoxia and involved in the Hedgehog signaling pathway, with over-expression in hepatocellular carcinoma (HCC) tissues or cell lines. Abnormal TUFT1 level was significantly related to tumor size, vascular invasion, positive hepatitis B e-antigen, advanced tumor-node-metastasis stage of HCC, patients with ascites, and shorter overall survival and disease-free survival. Interfering TUFT1 transcription could markedly suppress the growth and metastasis of high TUFT1 MHCC-97H cell lines in vitro through accelerating apoptosis. Moreover, increasing TUFT1 expression might promote the growth and metastasis of low TUFT1 Hep3B cell lines in vitro. The data suggested that TUFT1 is involved in HCC progression via the mechanism of inhibiting apoptosis and might serve as a potential therapeutic target for inhibiting HCC growth.